(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 8.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 226.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.76%.
Veracyte's revenue in 2025 is $463,393,000.On average, 3 Wall Street analysts forecast VCYT's revenue for 2025 to be $39,262,482,023, with the lowest VCYT revenue forecast at $39,168,269,546, and the highest VCYT revenue forecast at $39,377,369,557. On average, 4 Wall Street analysts forecast VCYT's revenue for 2026 to be $42,538,538,830, with the lowest VCYT revenue forecast at $41,843,496,657, and the highest VCYT revenue forecast at $43,557,020,346.
In 2027, VCYT is forecast to generate $46,838,089,288 in revenue, with the lowest revenue forecast at $45,789,769,906 and the highest revenue forecast at $48,219,089,139.